Combination treatment options for small-cell lung cancer - Authors' reply

Lancet Oncol. 2021 Mar;22(3):e84. doi: 10.1016/S1470-2045(21)00083-8.

Authors

Jonathan W Goldman¹, Luis Paz-Ares²

Affiliations

¹ David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.
² Department of Medical Oncology, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid 28041, Spain. Electronic address: lpazaresr@seom.org.

PMID: 33662292
DOI: 10.1016/S1470-2045(21)00083-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Etoposide
Humans
Lung Neoplasms* / drug therapy
Platinum*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
durvalumab
Platinum
Etoposide
tremelimumab